anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing an enzyme secreted from Bacillus sp. is provided to dissolve platelet rich clot and to reduce brain infarct. CONSTITUTION: A pharmaceutical composition for preventing and treating brain infarct contains 0.1-0.5 weight% of Cheonggukjang kinase as an active ingredient. The Cheonggukjang kinase has an amino acid of sequence number 1. A method for preparing the Cheonggukjang kinase comprises: a step of amplifying with a primer for amplifying aprE2 gene from Bacillus strain; a step of cloning the amplified aprE2 gene to a vector to obtain a recombinant plasmid and introducing the recombinant plasmid to Bacillus strain; a step of culturing recombinant strain; a step of centrifuging the strain at 2-10°C and collecting supernatant to remove the strain; a step of adding 80% ammonium sulfate and precipitating at 3-5°C for 10-25 hours; and a step of dissolving the precipitate using hydrochloric acid, dialyzing, and freeze-drying. A health food for preventing and treating brain infarct contains Cheonggukjang kinase as an active ingredient. The health food is used in the form of tablet, capsule, powder, granule, liquid, and pill.
The present invention provides a transgenic nonhuman mammal, preferably a rodent, comprising two human immunoglobulin loci, wherein one of two said human immunoglobulin loci is a human heavy chain locus and the other locus is a human light chain locus; and wherein only one of said loci is of a transchromosome. In some transgenic nonhuman mammals, the endogenous mammalian heavy chain locus and at least one mammalian light chain locus are inactivated. In some such transgenic nonhuman mammals, the endogenous mammalian heavy chain locus and kappa light chain locus are inactivated. The present invention further provides methods of generating a plurality of B cells from a transgenic nonhuman mammal expressing human antibody sequences. Additional methods of the invention comprise fusing the plurality of B cells with immortalized cells to form hybridomas. The present invention also provides methods of generating a human sequence antibody from a transgenic nonhuman mammal.
A method of producing a fused empty two-piece hard-shell (FETH) capsule and filling said capsule through a top opening on the center of a dome. The FETH comprises a cap portion and a body portion. A center hole is provided within a dome of either the cap portion or the body portion. The cap portion and the body portion are telescoped to form a closed unit and the portions are fused together. The FETH capsule is filled by dispensing a liquid from a nozzle into the center hole and then sealing the fill hole after the nozzle is removed. The method allows for (i) a reduction in the size of air bubbles, (ii) the elimination of any need for post-filling banding or sealing, (iii) the use of a variety of materials for the shell, eliminating the need for specially designed capsule materials that are liquid-friendly and (iv) streamlining the traditional liquid filling process and allowing for one continuous process. The capsules filled by the new methods hold 10-15% more liquid and thus offer a competitive advantage to soft gel capsules in terms of costs and efficiency.
The purpose of the proposed clinical trial is to demonstrate the safety and efficacy of intravascular hypothermia as part of the early hospital management and treatment for acute cervical SCI. Each year in the US, there are over 11,000 new cases of para- and quadriplegia and 100,000 new cases of partial but permanent neurological losses due to acute SCI. Thus the potential for clinical hypothermia following SCI to improve neurological outcome has significant value. Many patients suffering SCI become permanently dependent on caretakers and become a financial liability to both the family and society. Hypothermia has the potential to improve outcome so that more patients suffering SCI can regain independent motor and sensory function and remain economically productive members of society. The use of modest hypothermia through intravascular cooling may ultimately lead to better care of the patient with acute SCI and may also have more widespread uses in patients presenting with stroke or cardiac arrest. In the long-term, this research may lend support to the use of hypothermia that could in turn save money for the patients, hospitals, the government and society as a whole.
The participant will receive a low-dose washed microbiota suspension, with a bacterial quantity equivalent to the conventional clinical treatment dose. The washed microbiota suspension will be administered once on the first day, followed by placebo of equal volume for the next 3 days.
Asthma has high prevalence and morbidity among adolescents, especially urban Hispanic and African American teenagers. Despite this, few interventions have specifically targeted adolescents. School-based and web-based asthma interventions have shown to be effective with younger children, yet few have been developed and tested for adolescents. Investigators have developed Camp Air, an engaging dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. Camp Air consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback. The investigators will conduct a two group randomized pilot trial with up to 80, 9th - 12th graders with uncontrolled asthma in order (a) to assess the preliminary intervention effects of Camp Air, and (b) to evaluate the feasibility and acceptability of Camp Air. In order to evaluate CAMP Air's utility as both a school- and home-based intervention, adolescents will be enrolled from two sites: 1) NYC public schools (n=up to 38), or 2) the national asthma community at large (n=up to 42). Investigators will also evaluate the reach, acceptability, generalizability, and sustainability of Camp Air using the RE-AIM approach. Investigators hypothesize that over one month post-intervention, relative to controls, Camp Air participants will show significantly greater improvement in asthma-related outcomes. Investigators also hypothesize that ratings and software usage indices will demonstrate that Camp Air is a feasible, usable, and acceptable intervention for use with adolescents. Investigators will also explore evidence of a dose-response in which participants who spend more time engaged with the e-training materials show greater positive change.
Participants randomized into this arm will receive standard voice call reminders + loss aversion text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include loss aversion framing.
Extraocular ophthalmic preparations or devices useful as therapeutic, diagnostic lubricating or protective agents are disclosed. Perfluorocarbon films or gels are employed extraocularly as contact lenses. Liquid perfluorocarbons and substituted derivatives are the active components of the ophthalmic preparations. The neat perfluorocarbon liquids are not aqueous, wherefore, isotonicity and pH need not be considered in their preparation. Liquid sterility may be maintained without the addition of preservatives. Cornea and conjunctiva surfaces are provided with greater amounts of oxygen when the perfluorcarbon liquids are employed as eye drops. Transparent contact lenses having oxygen permeable properties are provided by the extraocular perfluorocarbon films or discs. Emulsions of perfluorocarbons in water are also suitable for all of the above uses and as carriers for drugs, antibiotics, hormones and therapeutic agents.
A modular service system is provided for a variety of diagnostic system modalities, manufacturers, and types. The system includes a uniform service platform which incorporates components for interfacing with different system types. The interface components include configuration libraries or files identifying the system type, as well as file names, content, locations, and so forth. One or more connectivity modules are provided for accessing and transferring data files from a modality system. The modular service system may be configured to cooperate with one or more such modality systems in a network arrangement. File translators are provided for converting individual files from modality, type or manufacturer-specific formats to more standard formats needed by the service platform.
The computer based APT-3 intervention will be delivered in a hybrid model that will combine in-person therapy sessions at Shirley Ryan AbilityLab and practice sessions which will be completed remotely. The dosing of each intervention training will be 30 minutes per day, 5 days a week, for 4 weeks (10 hours total over 4 weeks). The difficulty of the tasks in both interventions will increase progressively as the participants improve in their skills. APT-3 treatment will be administered by a trained and certified speech-language pathologist.
In response to the growing significance of the Short Physical Performance Battery (SPPB) in Alzheimer's Disease and Related Dementias (AD/ADRD) research, this project aims to create a mobile application that enhances physical and cognitive assessments. The SPPB has proven its value in evaluating lower extremity function and mobility in older adults, providing predictive insights into declines in daily living activities, falls, hospitalization, disability, and mortality. Moreover, recent research has revealed the potential of SPPB in detecting cognitive decline through gait and hand movement analysis at various stages of AD and Mild Cognitive Impairment (MCI). Recognizing the need for accessible and automated assessment tools, this project endeavors to design a mobile app with multi-fold functionality. It will guide users through SPPB tests, offer real-time performance scoring, and facilitate frequent, objective, and accurate physical and cognitive assessments. This is particularly critical for monitoring the progression of ADRD, identifying subtle physical changes indicative of cognitive decline, and enabling timely interventions tailored to patients' evolving needs.
The absolute oral bioavailability of PRISTIQ after oral administration is about 80%. Mean time to peak plasma concentrations (Tmax) is about 7.5 hours after oral administration. 

A food-effect study involving administration of PRISTIQ to healthy subjects under fasting and fed conditions (high-fat meal) indicated that the Cmax was increased about 16% in the fed state, while the AUCs were similar. This difference is not clinically significant; therefore, PRISTIQ can be taken without regard to meals [see Dosage and Administration (2.1)]. 

The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration. The desvenlafaxine volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.
BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer mortality globally. Lymph node metastasis and immunosuppression are main factors of poor prognosis in CRC patients. Lysyl oxidase like 1 (LOXL1), part of the lysyl oxidase (LOX) family, plays a yet unclear role in CRC. This study aimed to identify effective biomarkers predictive of prognosis and efficacy of immunotherapy in CRC patients, and to elucidate the prognostic value, clinical relevance, functional and molecular features, and immunotherapy predictive role of LOXL1 in CRC and pan-cancer.
METHODS: Weighted gene co-expression network analysis (WGCNA) was employed to explore gene modules related to tumor metastasis and CD8 + T cell infiltration. LOXL1 emerged as a hub gene through differential gene expression and survival analysis. The molecular signatures, functional roles, and immunological characteristics affected by LOXL1 were analyzed in multiple CRC cohorts, cell lines and clinical specimens. Additionally, LOXL1's potential as an immunotherapy response indicator was assessed, along with its role in pan-cancer.
RESULTS: Turquoise module in WGCNA analysis was identified as the hub module associated with lymph node metastasis and CD8 + T cell infiltration. Aberrant elevated LOXL1 expression was observed in CRC and correlated with poorer differentiation status and prognosis. Molecular and immunological characterization found that LOXL1 might mediate epithelial-mesenchymal transition (EMT) process and immunosuppressive phenotypes of CRC. Functional study found that LOXL1 enhanced tumor cell proliferation, migration and invasion. Moreover, high LOXL1 levels corresponded to reduced CD8 + T cell infiltration and predicted poor clinical outcomes of immunotherapy. Similar trends were also observed at the pan-cancer level.
CONCLUSIONS: Our findings underscore the critical role of LOXL1 in modulating both malignancy and immunosuppression in CRC. This positions LOXL1 as a promising biomarker for predicting prognosis and the response to immunotherapy in CRC patients.
FIELD: medicine, oncology, preparative biochemistry. SUBSTANCE: invention relates to the human isolated and purified protein oncoinhibin produced by erythroblastoid cells. Oncoinhibin shows an antineoplastic activity against breast carcinoma (MCF-7) and uterus carcinoma HeLa cellular lines and proliferative effect on human prepuce normal fibroblasts. Method of preparing oncoinhibin involves incubation of human erythroblastoid cells (K-562) on media, collection of condition cellular media, isolation and purification of human oncoinhibin. Pharmaceutical composition comprises oncoinhibin and a pharmaceutically acceptable carrier. EFFECT: preparing a new factor for the growth stimulation of normal cell. 7 cl, 45 dwg, 9 tbl
* Use aseptic technique throughout the entire reconstitution process.
  * If the patient uses more than one vial per injection, reconstitute each vial according to the following instructions.
    1. Allow the vials of FEIBA and Sterile Water for Injection (diluent) to reach room temperature, if refrigerated.
    2. Remove the plastic caps from the concentrate and diluent vials.
    3. Wipe the stoppers of both vials with a sterile alcohol swab and allow them to dry prior to use.
    4. Open the package of BAXJECT II Hi-Flow device by peeling away the lid completely without touching the inside (Fig. A). Do not remove the device from the package. Do not touch the clear spike.
    5. Place the diluent vial on a flat and solid surface. Turn the package over and insert the clear plastic spike through the diluent stopper by pressing straight down (Fig. B).
    6. Grip the BAXJECT II Hi-Flow device package at the edges and pull the package off the device (Fig. C). Do not remove the blue protective cap from the BAXJECT II Hi-Flow device. Do not touch the purple spike.
    7. Turn the system over, so that the diluent vial is on top. Quickly insert the purple spike of the BAXJECT II Hi-Flow device fully into the FEIBA vial. The vacuum will draw the diluent into the FEIBA vial (Fig. D). The connection of the two vials should be done expeditiously to close the open fluid pathway created by the first insertion of the spike to the diluent vial.
    8. Gently swirl (do not shake) the vial until FEIBA is completely dissolved. Make sure that FEIBA has been dissolved completely; otherwise, active material will not pass through the device filter. The reconstituted solution should be inspected visually for particulate matter before administration. The solution should be discarded if it is not clear or is discolored.
    9. After reconstitution of FEIBA is complete, the injection or infusion should begin immediately and must be completed within three hours following reconstitution. Do not refrigerate after reconstitution. Discard unused portion.
Two forms for AYA caregivers (n=10). Each form consists of 25 to 30 items. Forms for AYA caregivers only include items from the financial burden domain. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
The disclosure provides methods, systems, and computer readable media for calibrating user responses to questions. The method may comprise presenting, with the aid of a computer system and an interactive display operatively coupled to the computer system, a query to a user. The query may relate to the user's dietary consumption, exercise, health condition or mental condition. The system may receive from the user a response to the query. The system may interpret a user's response to a query based on a set of reference information. The set of reference information may comprise a pictorial depiction of portion size of the dietary consumption, exertion level of the exercise, existing state of the health condition or existing state of the mental condition.
Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
PROBLEM TO BE SOLVED: To provide an arithmetic processing apparatus capable of processing the blending concentration of an antiseptic, by inputting blending components and concentration in an aqueous emulsified composition by fixed steps for calculation. SOLUTION: The kinds and the blending concentrations of plural oil agents, solubilizer, nonionic surfactant and antiseptic are inputted in numerical values as a step 1. The blending concentration of the antiseptic is calculated through the following 12 steps. The solubilization concentration in a water phase is calculated by the step 3, the partition coefficient of an oil phase-water phase in a single system of the antiseptic is calculated in each oil agent from the solubilization concentration by the step 5 and the partition coefficient of the oil phase-water phase of the antiseptic in the mixed system of each oil agent is calculated from the volume ratio of each oil agent and the partition coefficient of the oil phase-water phase in the single system by the step 6.  Then the volume ratio of the oil phase and the water phase contained in the emulsified composition is calculated by the step 7, a liberation ratio is calculated by the step 8 and the optimal acquired preservation force concentration is calculated by the steps 12 and 13. The blending concentration of the antiseptic can be properly calculated in a short time.
PURPOSE:To easily peel and remove a wrapper from a carrier in opening a package contg. a sheetlike tape comprising the carrier coated with a self-adhesive layer and to stick the tape without causing wrinkles to an adhered by temporarily bonding the carrier to the inside surface of the wrapper in a specific manner. CONSTITUTION:In a package contg. a sheetlike tape comprising a carrier 5 coated with a self-adhesive layer 4 pref. contg. a drug, the carrier 5 is temporarily bonded to the inside surface of a wrapper 2 in such a manner that the wrapper 2 can be easily peeled off.
PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
OBJECTIVES: I. Identify the toxicity associated with increasing doses of monoclonal antibody F19 (BIBH-1) administered weekly by intravenous infusion in patients with unresectable, advanced or metastatic fibroblast activation protein-positive colorectal cancer. II. Determine the dose limiting toxicity and maximum tolerated dose of this drug in these patients. III. Measure induction titers of human anti-human antibody to BIBH-1 and correlate immunologic-related clinical effects. IV. Determine the pharmacokinetics, biodistribution, and imaging characteristics of increasing intravenous doses of the drug. V. Document tumor responses in this patient population.

OUTLINE: This is a dose escalation, open label, multicenter study. Patients receive monoclonal antibody F19 (BIBH-1) IV over 60 minutes weekly for 12 weeks. The first, fifth, and ninth treatments are combined with iodine I 131. Patients with stable or responding disease may continue treatment for up to 12 months. The dose of BIBH-1 is escalated in cohorts of 3-6 patients until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. Patients are followed at 1 month.

PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for this study within 8 months.
To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
Accumulating evidence suggests that berberine (BBR) exhibits anti-cancer effects in hepatocellular carcinoma (HCC). However, the mechanisms by which BBR regulates the immunological microenvironment in HCC has not been fully elucidated. In this study, a mouse model of orthotopic HCC is established and treated with varying doses of BBR. BBR showed effectiveness in reducing tumor burden in mice with HCC. Cytometry by time-of-flight depicted the alterations in the tumor immune landscape following BBR treatment, revealing the enhancement in the T lymphocytes effector function. In particular, BBR decreased the proportion of TCRbhiPD-1hiCD69+CD27+ effector CD8+ T lymphocytes and increased the proportion of Ly6ChiTCRb+CD69+CD27+CD62L+ central memory CD8+ T lymphocytes. Single-cell RNA sequencing further elucidates the effects of BBR on transcriptional profiles of liver immune cells and confirms the phenotypical heterogeneity of T lymphocytes in HCC immune microenvironment. Additionally, it is found that BBR potentially regulated the antitumor immunity in HCC by modulating the receptor-ligand interaction among immune cells mediated by cytokines. In summary, the findings improve the understanding of BBR's impact on protecting against HCC, emphasizing BBR's role in regulating intrahepatic T cell heterogeneity. BBR has the potential to be a promising therapeutic strategy to hinder the advancement of HCC.